WhiteBook2_Part2 - 51

Appendix
Genome-wide CRISPR/Cas9 screen in intestinal organoids for
identification and molecular characterization of therapeutic targets to
enhance tissue regeneration
Gut microbiota-dependent tryptophan metabolism: role in disease
pathogenesis and therapeutic target
Harnessing Targeted Nanotheranostics to Reprogram Activated
Leukocytes in Inflammatory Bowel Disease
High-throughput and reproducible development of intestinal organoids
by microfluidics encapsulation in synthetic niches for intestinal bowel
disease research
Highly efficient and eco-innovative probiotic food supplement for
antibiotic-associated disorders prevention
Identification and characterization of enteric nervous system stem cells
Identification of promoters and enhancers specific for inflammatory
bowel disease and its subtypes
Identifying microbiotal triggers of inflammatory bowel disease through
the lens of the immune system
Impact of maternal Adrenomedullin on the Microbiome and Gut health:
insights into preventing chronic intestinal disorders
Innovative technology solutions to explore effects of the microbiome on
intestine and brain pathophysiology
Investigating the regulation of iron homeostasis by erythroferrone and
therapeutic applications
Investigation of the role and mechanism of action of NOD2-mediated
isoform selective PI3K signalling in gut immunity and inflammation
Mapping and modulating integrin mediated interactions
Microbial therapy against gut inflammation
Microbiota and immune responses at weaning predict the susceptibility
to chronic inflammatory diseases in adulthood
Modulation of intestinal barrier function and inflammation via butyratepromoting
dietary fibre
Molecular, morphological, and functional requirements for
gastrointestinal serotonin release
Mucobiome-Mediated Immune Pathways in Inflammatory Bowel
Diseases
Multifunctional polymeric film-based drug delivery system for oral antiTNF-alpha-based
inflammatory bowel disease therapy
Nanoengineered magnetoresponsive diagnosis and personalized
treatment of pediatric inflammatory bowel disease
Neuroimmune activation as a novel therapeutic approach for IBD
New siRNA Nanotherapy for Inflammatory Bowel Diseases, targeting
Janus kinases
Novel diagnostic and therapeutic approach to inflammatory bowel
disease based on functional characterization of patients: the CrUCCial
index
Novel smart glyco-nanomaterials as targeted therapeutics.
Novel Target for Treatment of Chronic Inflammatory Diseases
Obsidian Anastomotic SafeGuard - A powerful and efficient tissue
sealant method for reducing the anastomotic leak rate in colorectal
surgery
Paediatric Inflammatory Bowel Diseases Network for Safety, Efficacy,
Treatment and Quality improvement of care
207312
1495525
2703125
257561.28
50000
212933.76
212194.8
2304375
184590.72
1992578
1499235
195454.8
162806.4
147815.04
1555650
203852.16
207312
166320
172800
2000000
150000
5999178.75
2494500
195454.8
2219688.63
50000
5996000
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
Inflammatory
bowel disease
White Book 2: Part 2
48
WhiteBook2_Part2

Table of Contents for the Digital Edition of WhiteBook2_Part2
